Fosamax and Osteonecrosis of the Jaw: Examining the Causal Link

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

General Health Context and Legacy of Bisphosphonate Safety Information

The legacy of general health and science information has long served as a foundational resource for public understanding of medical conditions and therapeutic interventions. Within this broad context, discussions of medication safety and adverse effects have been central, particularly as they relate to widely prescribed treatments. One such area of focus has been the class of bisphosphonate drugs, commonly used to manage bone density disorders. Among these, Fosamax (alendronate) has been extensively studied and prescribed, leading to a substantial body of general health literature examining its risk profile. This heritage of accessible health communication has effectively translated complex pharmacological data into actionable knowledge for patients and providers alike, emphasizing the importance of informed decision-making in therapeutic contexts.

Transition from General Health to Occupational Exposure Concerns

Transitioning from this general health foundation, a more specialized concern emerges regarding occupational exposure scenarios. While the general health discourse primarily addresses patient populations receiving Fosamax for medical indications, the question of causation in occupational settings introduces distinct considerations. Workers in pharmaceutical manufacturing, healthcare administration, or waste management may encounter Fosamax through routes not typical of prescribed use, such as inhalation of dust or dermal contact during production. This pivot from patient-centered risk assessment to occupational exposure concern necessitates a reexamination of the same core question—whether Fosamax can cause osteonecrosis of the jaw—but within a framework that accounts for chronic, low-level exposure in non-therapeutic contexts. Such a shift underscores the need for targeted occupational health surveillance and risk communication strategies.

Medical Evidence: Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Causation Considerations

Mechanistic pathways linking Fosamax to ONJ involve the drug's effect on bone remodeling. Bisphosphonates like alendronate inhibit osteoclast activity, reducing bone turnover. In the jawbone, which has high remodeling rates, this suppression can impair healing after dental procedures or local trauma, leading to necrotic bone exposure. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique biology of the jawbone that may predispose it to ONJ under bisphosphonate therapy. Regarding causation considerations for affected patients, the evidence indicates a plausible association between Fosamax use and ONJ, particularly in the presence of risk factors such as invasive dental procedures or cancer. The timeline between exposure and documented harm can range from days to months, and the risk appears to increase with longer duration of bisphosphonate use. However, the low incidence in placebo-controlled trials suggests that ONJ is not a common adverse effect. For patients who develop ONJ, discontinuation of Fosamax may lead to symptom relief, but recurrence upon rechallenge indicates a drug-specific effect.

Adequacy of Warnings and Clinical Management

Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on osteonecrosis of the jaw, detailing risk factors, clinical presentation, and management recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The warnings advise discontinuing use if severe symptoms develop and note that most patients have relief after stopping. The label also mentions that the risk may increase with duration of exposure and that discontinuation before invasive dental procedures may reduce risk. These warnings provide clinicians and patients with information to make informed decisions about Fosamax therapy and to monitor for signs of ONJ. In summary, Fosamax is associated with osteonecrosis of the jaw, with a variable onset timeline and increased risk in patients with certain predisposing factors. The prescribing information includes warnings and management guidance, though the overall incidence in clinical trials was low. Patients and healthcare providers should weigh the benefits of Fosamax for osteoporosis and other indications against the potential risk of ONJ, especially in those undergoing dental procedures or with other risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and what is it used for?

Can Fosamax cause osteonecrosis of the jaw?

Yes, osteonecrosis of the jaw (ONJ) has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk may increase with duration of exposure and is higher in patients with risk factors such as invasive dental procedures, cancer, or poor oral hygiene (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What are the symptoms of osteonecrosis of the jaw?

ONJ is characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How long does it take for Fosamax to cause jaw problems?

The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.